Structure Therapeutics (ADR) (GPCR)
Develops oral small-molecule medicines for metabolic, cardiovascular, and pulmonary conditions.
Something off on this page? Send us feedback.
Develops investigational oral small-molecule medicines against GPCR targets. Its most advanced program, aleniglipron, targets obesity, while other candidates address metabolic, cardiovascular, and pulmonary disorders.
Develops investigational oral small-molecule medicines through structure-based discovery and computational chemistry, focused on GPCR targets. Aleniglipron, an oral nonpeptide GLP-1 receptor agonist for obesity, is its most advanced candidate.
Headquartered in South San Francisco, with R&D operations in Shanghai, it also develops ACCG-2671, ANPA-0073, LTSE-2578, and ACCG-3535 for metabolic, cardiovascular, and pulmonary disorders. It has no commercial-product sales or product revenue and remains an investigational clinical-development business today.
Progress depends on clinical-study timing and outcomes, regulatory filings and approvals, third-party service providers, intellectual-property protection, manufacturing and commercialization planning, and continued financing.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 7, 2026 | Canaccord Genuity | Target | Target: $101 | Target: $111 |
| Jun 11, 2026 | H.C. Wainwright | Target | Target: $90 | Target: $70 |
| Apr 27, 2026 | Canaccord Genuity | Target | Target: — | Target: $101 |
| Mar 17, 2026 | BMO Capital | Target | Target: $100 | Target: $145 |
| Jan 20, 2026 | Guggenheim | Reiterate | Rating: —Target: — | Target: $140 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.34B · Total debt $6.2M · Total assets $1.43B · Shareholders' equity $1.35B
- Revenue
- $0
- Operating income
- −$118.6M
- Net income
- −$106.2M
No dividends on record.
| Institutions | 94.74% | 67.56M ADS | |
|---|---|---|---|
| 202 holders · as of Jun 30, 2026 | |||
| Insiders | 0.54% | 383.6K ADS | |
| 8 holders · as of Sep 22, 2026 | |||
| Strategic holders | 2.08% | 1.48M ADS | |
| 1 holder · as of Nov 14, 2025 | |||
| Other | 2.64% | 1.88M ADS | |
| remainder | |||
71.31M ADS (1 ADS = 3 ordinary shares) as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (71.31M in the company's Sep 23, 2026 report, 57.57M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 10.95% | 7.81M ADS | as of Jun 30, 2026 |
Wellington Management Group LLPInstitution | 10.35% | 7.38M ADS | as of Jun 30, 2026 |
Avoro Capital Advisors LLCInstitution | 9.19% | 6.56M ADS | as of Jun 30, 2026 |
Jupiter Topco LLCInstitution | 7.30% | 5.20M ADS | as of Jun 30, 2026 |
Deep Track Capital, LPInstitution | 6.65% | 4.74M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 21, 2026 | Crespo Blas Coll | officer: CHIEF MEDICAL OFFICER | −4,008 | |
| Sep 1, 2026 | Xichen Lin | officer: CHIEF SCIENTIFIC OFFICER | −5,939 | |
| Aug 18, 2026 | Xichen Lin | officer: CHIEF SCIENTIFIC OFFICER | −3,939 | |
| Aug 4, 2026 | Xichen Lin | officer: CHIEF SCIENTIFIC OFFICER | −3,939 | |
| Jul 22, 2026 | FMR LLC | 10 percent owner, other: See Remark 1 | −17,452 |
- Novo Nordisk (ADR)
Marketed oral GLP-1 therapy for chronic weight management
- Eli Lilly
FDA-approved daily small-molecule oral GLP-1 obesity therapy
- Viking Therapeutics
Clinical-stage oral GLP-1/GIP candidate for obesity
- AstraZeneca (ADR)
Large-cap obesity pipeline competitor with an oral GLP-1 program
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Structure Therapeutics (ADR) | $37.20 | +1.03% | $2.12B | — | — | — | — |
| Novo Nordisk (ADR) | $39.44 | +0.08% | $176.83B | 9.9 | 16.2 | 3.5 | +1.3% |
| Eli Lilly | $1,170.23 | −0.02% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| Viking Therapeutics | $41.68 | +2.02% | $3.51B | — | — | — | — |
| AstraZeneca (ADR) | $168.45 | +0.05% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| Median | 25.2 | 16.2 | 4.2 | +6.4% |